Thelansis

Behçet’s Disease Market Outlook Thelansis’s “Behçet’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Behçet’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights...

  Behçet’s disease (BD) is an uncommon yet profoundly incapacitating vasculitis, primarily characterized by mucocutaneous manifestations, including orogenital ulcers and skin lesions. Notably, BD can affect various organ systems, such as the musculoskeletal, ocular, nervous, gastrointestinal, vascular, urogenital, and cardio-pulmonary systems, resulting in considerable morbidity and mortality. The diagnosis of BD is often delayed due to the variability and intermittency of symptoms, the necessity to exclude mimicking conditions, the absence of a specific blood test or disease marker, and a general lack of awareness about the disorder. The etiology of BD is unknown, with genetic predisposition potentially permitting specific infectious agents, particularly Streptococcus sanguis, or environmental factors to trigger inflammatory attacks resembling auto-inflammatory disorders through cross-reactions with oral mucosa antigens. The HLAB5101 antigen is implicated in 50-60% of BD cases, ...